
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 10-Q

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2025, or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to

Commission file number 0-17272

BIO-TECHNE CORPORATION
(Exact name of registrant as specified in its charter)

Minnesota
(State or other jurisdiction of
incorporation or organization)

41-1427402
(I.R.S. Employer
Identification No.)

614 McKinley Place N.E.
Minneapolis, MN 55413
(Address of principal executive offices) (Zip Code)

(612) 379-8854
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	TECH	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐

Non-accelerated filer ☐ Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2). ☐ Yes ☒ No

At October 30, 2025, 155,812,701 shares of the Company's Common Stock (par value \$0.01) were outstanding.

TABLE OF CONTENTS

Page

PART I: FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements (Unaudited)	1
	Condensed Consolidated Statements of Earnings and Comprehensive Income	1
	Condensed Consolidated Balance Sheets	2
	Condensed Consolidated Statements of Cash Flows	3
	Condensed Consolidated Statements of Stockholders' Equity	4
	Notes to Condensed Consolidated Financial Statements	5
	Note 1. Basis of Presentation and Summary of Significant Accounting Policies	5
	Note 2. Revenue Recognition	6
	Note 3. Selected Balance Sheet Information	8
	Note 4. Fair Value Measurements	10
	Note 5. Debt and Other Financing Arrangements	12
	Note 6. Leases	12
	Note 7. Supplemental Equity and Accumulated Other Comprehensive Income (Loss)	14
	Note 8. Earnings Per Share	15
	Note 9. Share-based Compensation and Other Benefit Plans	15
	Note 10. Other Income/(Expense)	16
	Note 11. Income Taxes	16
	Note 12. Segment Information	16
	Note 13. Restructuring	18
	Note 14. Subsequent Events	20
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	28
Item 4.	Controls and Procedures	28

PART II: OTHER INFORMATION

Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	29
Item 4.	Mine Safety Disclosures	29
Item 5.	Other Information	29
Item 6.	Exhibits	30
	SIGNATURES	31

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

**CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
AND COMPREHENSIVE INCOME**

*Bio-Techne Corporation and Subsidiaries
(in thousands, except per share data)
(unaudited)*

	<i>Quarter Ended September 30,</i>	
	<i>2025</i>	<i>2024</i>
Net sales	\$ 286,555	\$ 289,458
Cost of sales	98,443	106,441
Gross margin	188,112	183,017
Operating expenses:		
Selling, general and administrative	116,213	119,161
Research and development	24,241	23,869
Total operating expenses	140,454	143,030
Operating income	47,658	39,987
Other income (expense)	333	184
Earnings before income taxes	47,991	40,171
Income taxes	9,806	6,571
Net earnings	\$ 38,185	\$ 33,600
Other comprehensive income (loss):		
Foreign currency translation income (loss)	(2,850)	21,256
Unrealized gains (losses) on derivative instruments	(1,665)	(3,027)
Other comprehensive income (loss)	(4,515)	18,229
Comprehensive income	\$ 33,670	\$ 51,829
Earnings per share:		
Basic	\$ 0.25	\$ 0.21
Diluted	\$ 0.24	\$ 0.21
Weighted average common shares outstanding:		
Basic	155,464	158,531
Diluted	156,362	161,115

See Notes to Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED BALANCE SHEETS
Bio-Techne Corporation and Subsidiaries
(in thousands, except share and per share data)

	September 30, 2025 (unaudited)	June 30, 2025
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 144,962	\$ 162,186
Accounts receivable, less allowances of \$4,375 and \$4,215, respectively	183,897	206,876
Inventories	203,188	189,446
Current assets held-for-sale	—	12,332
Other current assets	77,460	37,460
Total current assets	<u>609,507</u>	<u>608,300</u>
Property and equipment, net	240,334	245,719
Right-of-use assets	70,725	73,399
Goodwill	978,912	980,935
Intangible assets, net	350,107	365,599
Other assets	276,563	283,916
Total assets	<u>\$ 2,526,148</u>	<u>\$ 2,557,868</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Trade accounts payable	\$ 30,157	\$ 25,311
Salaries, wages and related accruals	43,599	65,791
Accrued expenses	19,179	25,663
Contract liabilities	30,445	32,571
Income taxes payable	2,848	10,770
Operating lease liabilities - current	13,771	14,098
Other current liabilities	4,546	1,645
Total current liabilities	<u>144,545</u>	<u>175,849</u>
Deferred income taxes	11,273	6,169
Long-term debt obligations	300,000	346,000
Operating lease liabilities	80,702	83,960
Other long-term liabilities	23,814	27,082
Shareholders' equity:		
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	—	—
Common stock, par value \$.01 per share; authorized 400,000,000; issued and outstanding 155,749,477 and 154,972,196 respectively	1,557	1,550
Additional paid-in capital	946,118	911,089
Retained earnings	1,082,534	1,066,049
Accumulated other comprehensive loss	(64,395)	(59,880)
Total shareholders' equity	<u>1,965,814</u>	<u>1,918,808</u>
Total liabilities and shareholders' equity	<u>\$ 2,526,148</u>	<u>\$ 2,557,868</u>

See Notes to Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Bio-Techne Corporation and Subsidiaries

(in thousands)

(unaudited)

	<i>Quarter Ended September 30,</i>	
	<i>2025</i>	<i>2024</i>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net earnings	\$ 38,185	\$ 33,600
Adjustments to reconcile net earnings to net cash provided by operating activities:		
Depreciation and amortization	24,340	28,137
Deferred income taxes	5,275	(5,340)
Stock-based compensation expense	11,682	10,184
(Gain) Loss on equity method investment	(294)	(374)
(Gain) Loss on investments	(2,054)	—
Asset impairment restructuring	—	6,039
Leases, net	(912)	445
Recovery of assets held-for-sale	(6,789)	—
Other operating activity	1,001	935
Change in operating assets and operating liabilities, net of acquisition:		
Trade accounts and other receivables, net	22,392	21,563
Inventories	(14,002)	(2,805)
Prepaid expenses	380	(3,158)
Trade accounts payable, accrued expenses, contract liabilities, and other	(2,115)	(10,911)
Salaries, wages and related accruals	(22,101)	(8,246)
Income taxes payable	(27,403)	(6,180)
Net cash provided by (used in) operating activities	<u>27,585</u>	<u>63,889</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from sale of available-for-sale investments	—	1,085
Additions to property and equipment	(5,363)	(9,172)
Distributions from Wilson Wolf	1,351	1,403
Investment in Spear Bio	—	(15,000)
Proceeds from sale of assets held-for-sale	4,617	—
Net cash provided by (used in) investing activities	<u>605</u>	<u>(21,684)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Cash dividends	(12,444)	(12,688)
Proceeds from stock option exercises	23,495	25,101
Repurchases of common stock	(24)	—
Repayments of long-term debt	(46,000)	(19,000)
Taxes paid on RSUs and net share settlements	(9,231)	(4,984)
Net cash provided by (used in) financing activities	<u>(44,204)</u>	<u>(11,571)</u>
Effect of exchange rate changes on cash and cash equivalents	(1,210)	5,115
Net change in cash and cash equivalents	<u>(17,224)</u>	<u>35,749</u>
Cash and cash equivalents at beginning of period	162,186	151,791
Cash and cash equivalents at end of period	<u>\$ 144,962</u>	<u>\$ 187,540</u>
Supplemental disclosure of cash flow information:		
Cash paid for income taxes	\$ 30,812	\$ 16,490
Cash paid for interest	\$ 4,822	\$ 5,205

See Notes to Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

Bio-Techne Corporation and Subsidiaries

(in thousands)

(unaudited)

	<i>Common Stock</i>		<i>Additional</i>	<i>Retained</i>	<i>Accumulated</i>	
	<i>Shares</i>	<i>Amount</i>	<i>Paid-in</i>	<i>Earnings</i>	<i>Other</i>	<i>Total</i>
			<i>Capital</i>		<i>Comprehensive</i>	
					<i>Loss</i>	
Three months ended September 30, 2025						
Balances at June 30, 2025	154,972	\$ 1,550	\$ 911,089	\$ 1,066,049	\$ (59,880)	\$ 1,918,808
Net earnings				38,185		38,185
Other comprehensive income					(4,515)	(4,515)
Share repurchases	(1)	0		(24)		(24)
Common stock issued for exercise of options	625	6	21,477	(5,895)		15,588
Common stock issued for restricted stock awards	110	1	(1)	(3,337)		(3,337)
Cash dividends (\$0.08 per share)				(12,444)		(12,444)
Stock-based compensation expense			11,543			11,543
Common stock issued to employee stock purchase plan	43	0	2,012			2,012
Employee stock purchase plan expense			(2)			(2)
Balances at September 30, 2025	155,749	\$ 1,557	\$ 946,118	\$ 1,082,534	\$ (64,395)	\$ 1,965,814

	<i>Common Stock</i>		<i>Additional</i>	<i>Retained</i>	<i>Accumulated</i>	
	<i>Shares</i>	<i>Amount</i>	<i>Paid-in</i>	<i>Earnings</i>	<i>Other</i>	<i>Total</i>
			<i>Capital</i>		<i>Comprehensive</i>	
					<i>Loss</i>	
Three months ended September 30, 2024						
Balances at June 30, 2024	158,216	\$ 1,582	\$ 820,337	\$ 1,325,247	\$ (78,316)	\$ 2,068,850
Net earnings				33,600		33,600
Other comprehensive income					18,229	18,229
Common stock issued for exercise of options	577	6	23,224	(2,338)		20,892
Common stock issued for restricted stock awards	50	1	1	(2,646)		(2,644)
Cash dividends (\$0.08 per share)				(12,688)		(12,688)
Stock-based compensation expense			10,146			10,146
Common stock issued to employee stock purchase plan	35	0	2,227			2,227
Employee stock purchase plan expense			38			38
Balances at September 30, 2024	158,878	\$ 1,589	\$ 855,973	\$ 1,341,175	\$ (60,087)	\$ 2,138,650

See Notes to the Condensed Consolidated Financial Statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Bio-Techne Corporation and Subsidiaries
(unaudited)

Note 1. Basis of Presentation and Summary of Significant Accounting Policies:

The interim Condensed Consolidated Financial Statements of Bio-Techne Corporation and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These interim unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2025, included in the Company's Annual Report on Form 10-K for fiscal 2025. A summary of significant accounting policies followed by the Company is detailed in the Company's Annual Report on Form 10-K for fiscal 2025. The Company follows these policies in preparation of the interim unaudited Condensed Consolidated Financial Statements.

Investments: In September 2025, the Company received MDxHealth SA ("MDxHealth") stock as part of our divestiture of Exosome Diagnostics. The fair value of the stock was \$8.7 million at September 30, 2025 and is included within Other assets on the Condensed Consolidated Balance Sheets.

In July 2024, the Company paid \$15 million to enter into an investment in Spear Bio. This investment is accounted for under the cost-method as we own less than 20% of the outstanding stock and we concluded that we do not have significant influence. Under the cost-method, the fair value is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. No such events or changes in circumstances were identified in the period ended September 30, 2025. The Company's total investment of \$15 million is included within Other assets on the Condensed Consolidated Balance Sheets.

In December 2021, the Company paid \$25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract is triggered upon Wilson Wolf achieving approximately \$92 million in annual revenue or \$55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional \$232 million to acquire 19.9% of Wilson Wolf.

Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, which requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately \$226 million in annual revenue or \$136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately \$1 billion plus potential consideration for revenue in excess of the revenue milestone.

Legal Matters: The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. There have been no material changes since the filing of the Company's Annual Report on Form 10-K for fiscal 2025.

[Table of Contents](#)

In August 2024, 791,204 shares of outstanding vested stock options related to former employees expired which were excluded from the Company's dilutive EPS calculation for the period ended September 30, 2024. Of the 791,204 shares, 779,084 shares belonged to the Company's former CEO. The expiration date of these options was previously under dispute. The dispute with the former CEO was resolved through a binding arbitration award during the quarter ended March 31, 2025 for which the Company paid \$37.2 million inclusive of interest and legal fees. The dispute regarding the remaining 12,120 shares was resolved during the quarter ended March 31, 2025 resulting in total payments of \$0.5 million.

Litigation charges were immaterial during the quarters ended September 30, 2025 and 2024. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in Other current liabilities and Other liabilities on the Condensed Consolidated Balance Sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows.

Recently Adopted Accounting Pronouncements

In November 2023, the FASB issued *ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280)*, which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company adopted this guidance beginning with our annual report for fiscal 2025 and interim periods thereafter on a retrospective basis.

Relevant New Standards Issued Not Yet Adopted

In December 2023, the FASB issued *ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740)*, which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

In November 2024, the FASB issued *ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40)*, which requires incremental disclosures on purchases of inventory, employee compensation, depreciation, intangible asset amortization, and other expenses. The Company will adopt this guidance beginning with our annual report for fiscal 2027. This accounting standard will increase disclosures in the Company's annual reporting but will have no impact on reported income statement expenses.

In August 2025, the FASB issued *ASU 2025-05, Financial Instruments—Credit Losses (Topic 326)*, which requires incremental disclosures on estimating expected credit losses. The Company will adopt this guidance beginning with our annual report for fiscal 2027. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

In September 2025, the FASB issued *ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40)*, which requires incremental disclosures on recording intangibles for internal-use software. The Company will adopt this guidance beginning with our annual report for fiscal 2029. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, on our unaudited Condensed Consolidated Financial Statements.

Note 2. Revenue Recognition:

Consumables revenues consist of specialized proteins, immunoassays, antibodies, reagents, blood chemistry and blood gas quality controls, and hematology instrument controls that are typically single-use products recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support, and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at point in time.

[Table of Contents](#)

We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date.

The Company elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance. The Company's unfulfilled performance obligations for contracts with an original length greater than one year were not material as of September 30, 2025 and June 30, 2025.

Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract's transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts' inception.

Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.

Contract assets include revenues recognized in advance of billings. Contract assets are included within Other current assets in the accompanying Condensed Consolidated Balance Sheets as the amount of time expected to lapse until the Company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over a period of less than one year. Contract assets as of September 30, 2025 and June 30, 2025 are not material.

Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of September 30, 2025 and June 30, 2025 were approximately \$32.7 million and \$35.3 million, respectively. Contract liabilities as of June 30, 2025 subsequently recognized as revenue during the quarter ended September 30, 2025 were approximately \$13.2 million. Contract liabilities as of June 30, 2024 subsequently recognized as revenue during the quarter ended September 30, 2024 were approximately \$11.8 million. Contract liabilities in excess of one year are included in Other long-term liabilities on the Condensed Consolidated Balance Sheets.

Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material.

Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized.

The following tables present our disaggregated revenue for the periods presented.

Revenue by type is as follows (in thousands):

	<i>Quarter Ended</i> <i>September 30,</i>	
	<i>2025</i>	<i>2024</i>
Consumables	\$ 231,601	\$ 230,845
Instruments	21,826	26,206
Services	27,482	27,357
Total product and services revenue, net	\$ 280,909	\$ 284,408
Royalty revenues	5,646	5,050
Total revenues, net	<u>\$ 286,555</u>	<u>\$ 289,458</u>

[Table of Contents](#)

Revenue by geography is as follows (in thousands):

	<i>Quarter Ended September 30,</i>	
	<i>2025</i>	<i>2024</i>
United States	\$ 155,240	\$ 165,015
EMEA, excluding United Kingdom	65,128	59,063
United Kingdom	13,205	13,944
APAC, excluding Greater China	19,147	18,122
Greater China	24,786	24,321
Rest of World	9,049	8,993
Net sales	<u>\$ 286,555</u>	<u>\$ 289,458</u>

Note 3. Selected Balance Sheet Data:

Inventories:

Inventories consist of (in thousands):

	<i>September 30, 2025</i>	<i>June 30, 2025</i>
Raw materials	\$ 93,993	\$ 89,080
Finished goods ⁽¹⁾	114,878	106,188
Inventories	<u>\$ 208,871</u>	<u>\$ 195,268</u>

(1) Finished goods inventory of \$5,683 and \$5,822 is included within Other Assets in the September 30, 2025 and June 30, 2025, Condensed Consolidated Balance Sheets, respectively, as it is forecasted to be sold after the 12 months subsequent to the Condensed Consolidated Balance Sheets dates.

Property and Equipment:

Property and equipment consist of (in thousands):

	<i>September 30, 2025</i>	<i>June 30, 2025</i>
Land	\$ 8,133	\$ 8,151
Buildings and improvements	256,737	254,355
Machinery and equipment	244,188	245,924
Construction in progress	20,257	23,420
Property and equipment, cost	<u>529,315</u>	<u>531,850</u>
Accumulated depreciation and amortization	<u>(288,981)</u>	<u>(286,131)</u>
Property and equipment, net	<u>\$ 240,334</u>	<u>\$ 245,719</u>

Intangible Assets:

Intangible assets consist of (in thousands):

	<i>September 30, 2025</i>	<i>June 30, 2025</i>
Developed technology	\$ 579,531	\$ 620,062
Tradenames	94,393	152,648
Customer relationships	210,431	212,800
Patents	5,062	4,967
Other intangibles	<u>7,145</u>	<u>7,174</u>
Definite-lived intangible assets	<u>896,562</u>	<u>997,651</u>
Accumulated amortization	<u>(546,455)</u>	<u>(632,052)</u>
Total intangible assets, net	<u>\$ 350,107</u>	<u>\$ 365,599</u>

[Table of Contents](#)

Changes to the carrying amount of net intangible assets for the period ended September 30, 2025 consist of (in thousands):

	September 30, 2025
Beginning balance	\$ 365,599
Other additions	95
Amortization expense	(15,498)
Currency translation	(89)
Ending balance	<u>\$ 350,107</u>

The estimated future amortization expense for intangible assets as of September 30, 2025 is as follows (in thousands):

Remainder 2026	\$ 46,256
2027	58,682
2028	54,951
2029	40,870
2030	26,911
Thereafter	122,437
Total	<u>\$ 350,107</u>

Goodwill:

Changes to the carrying amount of goodwill for the period ended September 30, 2025 consist of (in thousands):

	<i>Protein Sciences</i>	<i>Diagnostics and Spatial Biology</i>	<i>Total</i>
June 30, 2025	\$ 426,776	\$ 554,159	\$ 980,935
Currency translation	(1,975)	(48)	(2,023)
September 30, 2025	<u>\$ 424,801</u>	<u>\$ 554,111</u>	<u>\$ 978,912</u>

We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2025. No indicators of impairment were identified as part of our assessment.

Other assets:

Other assets consist of (in thousands):

	September 30, 2025	June 30, 2025
Equity method investment in Wilson Wolf	\$ 234,925	\$ 235,983
Long-term inventory	5,683	5,822
Investment in Spear Bio	15,000	15,000
Investment in MDxHealth ⁽¹⁾	8,682	—
Notes receivable ⁽¹⁾	7,744	2,184
Other	4,529	24,927
Other assets	<u>\$ 276,563</u>	<u>\$ 283,916</u>

(1) Amounts relate to the completed divestitures of the Company's held-for-sale assets.

[Table of Contents](#)

Note 4. Fair Value Measurements:

The Company's financial instruments include cash and cash equivalents, available for sale investments, derivative instruments, accounts receivable, notes receivable, accounts payable, and long-term debt.

Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.

The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):

Balance Sheet Location		Total carrying value as of September 30, 2025	Fair Value Measurements Using Inputs Considered as		
			Level 1	Level 2	Level 3
Assets					
Exchange traded securities ⁽¹⁾	Other assets	\$ 8,682	\$ 8,682	\$ —	\$ —
Derivatives designated as hedging instruments - cash flow hedges	Other current assets	1,141	—	1,141	—
Notes receivable ⁽²⁾	Other current assets	4,873	—	—	4,873
Notes receivable ⁽²⁾	Other assets	7,744	—	—	7,744
Total assets		<u>\$ 22,440</u>	<u>\$ 8,682</u>	<u>\$ 1,141</u>	<u>\$ 12,617</u>
Liabilities					
Derivatives designated as hedging instruments - net investment hedge	Other long-term liabilities	\$ 16,481	\$ —	\$ 16,481	\$ —
Total liabilities		<u>\$ 16,481</u>	<u>\$ —</u>	<u>\$ 16,481</u>	<u>\$ —</u>

(1) Exchange traded securities received from the buyer in the sale of Exosome Diagnostics.

(2) Notes receivable relate to the divestiture of our businesses held-for-sale.

[Table of Contents](#)

Balance Sheet Location		Total carrying value as of June 30, 2025	Fair Value Measurements Using Inputs Considered as		
			Level 1	Level 2	Level 3
Assets					
Derivatives designated as hedging instruments - cash flow hedges	Other current assets	\$ 2,843	\$ —	\$ 2,843	\$ —
Note receivable ⁽¹⁾	Other current assets	3,078	—	—	3,078
Note receivable ⁽¹⁾	Other assets	2,184	—	—	2,184
Total assets		<u>\$ 8,105</u>	<u>\$ —</u>	<u>\$ 2,843</u>	<u>\$ 5,262</u>
Liabilities					
Derivatives designated as hedging instruments - net investment hedge	Other long-term liabilities	\$ 18,034	\$ —	\$ 18,034	\$ —
Total liabilities		<u>\$ 18,034</u>	<u>\$ —</u>	<u>\$ 18,034</u>	<u>\$ —</u>

(1) Note receivable relates to the divestiture of our business held-for-sale.

Fair value measurements of derivative instruments

The Company utilizes forward starting swaps designated as a cash flow hedge on forecasted debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company's forecasted variable interest long-term debt to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on a notional principal amount. The Company also uses a cross-currency swap contract to manage its exposure to foreign currency risk associated with the Company's net investment in its Swiss subsidiary.

The following table presents the contractual amounts of the Company's outstanding instruments (in millions):

Instruments	Designation	September 30, 2025	June 30, 2025
Forward starting swaps ⁽¹⁾	Cash flow hedge	\$ 200	\$ 200
Cross-currency swap ⁽²⁾	Net investment hedge	130	140

(1) In May 2021, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on \$200 million of notional principal. The effective date of the swap was November 2022 with the full swap maturing in November 2025.

(2) In July 2023, the Company entered into a pay-fixed rate, receive-fixed rate cross-currency swap contract with a total notional amount of \$150 million that was designated as a hedge to lock in the Swiss franc (CHF) rate for a portion of the Company's CHF net investment in its Lunaphore subsidiary in Switzerland. The objective of the hedge is to protect the net investment in the Company's CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has three remaining interim settlement dates, which will reduce the notional on the hedging instrument by \$10 million at each interim date, and will reduce the notional to \$110 million at maturity.

The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses within our Condensed Consolidated Financial Statements for the quarters ended September 30, 2025 and 2024 were as follows (in thousands):

	(Gain) Loss Recognized in Accumulated Other Comprehensive Loss	
	Quarter Ended September 30,	
	2025	2024
Cash flow hedges		
Forward starting swaps	\$ 3,009	\$ 5,010
Net investment hedges		
Cross-currency swap	(717)	5,165
Total	\$ 2,292	\$ 10,175

	(Gain) Loss Reclassified into Income		
	Quarter Ended		
	September 30,		
	2025	2024	Income Statement Classification
Cash flow hedges			
Forward starting swaps	\$ (1,921)	\$ (2,599)	Interest expense
Net investment hedges			
Cross-currency swap	(613)	(782)	Interest expense
Total	\$ (2,534)	\$ (3,381)	

Gains or losses related to the net investment hedges are classified as foreign currency translation adjustments in the schedule of changes in Accumulated Other Comprehensive Income (“AOCI”) in Note 7, as these items are attributable to the Company’s hedges of its net investment in foreign operations. Gains or losses related to the cash flow hedges are classified as Unrealized gains (losses) on cash flow hedges in the schedule of changes in AOCI in Note 7.

Fair value measurements of other financial instruments – The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.

Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the Condensed Consolidated Balance Sheets approximate fair value because of the short-term nature of these items.

Long-term debt – The carrying amounts reported in the Condensed Consolidated Balance Sheets for the amount drawn on our line-of-credit facility and long-term debt approximates fair value because our interest rate is variable and reflects current market rates.

Note 5. Debt and Other Financing Arrangements:

On August 31, 2022, the Company entered into a revolving line-of-credit and term loan governed by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of \$1 billion, which can be increased by an additional \$400 million subject to certain conditions. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the one-month Secured Overnight Financing Rate (SOFR) plus an applicable margin. The applicable margin is determined from the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 10 basis points.

The Credit Agreement matures on August 31, 2027 and contains customary restrictive and financial covenants and customary events of default. As of September 30, 2025 and June 30, 2025, the outstanding balance under the Credit Agreement was \$300.0 million and \$346.0 million respectively.

Note 6. Leases:

As a lessee, the Company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement date, operating lease right-of-use assets and liabilities are recognized based on the present value of lease payments over the lease term. The discount rate used to calculate present value is the Company’s incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. The Company recognizes operating lease expense on a straight-line basis over the lease term. Further, as part of our adoption of *ASC 842*, the Company also made the accounting policy elections to not capitalize short term leases (defined as a lease with a lease term that is less than 12 months) and to combine lease and non-lease components for all asset classes in determining the lease payments.

[Table of Contents](#)

The Condensed Consolidated Financial Statements include the following amounts related to operating leases where the Company is the lessee (\$ in thousands):

		<i>Quarter Ended September, 30</i>	
		2025	2024
Condensed Consolidated Statements of Earnings			
Fixed operating lease expense		\$ 4,409	\$ 4,385
Variable operating lease expense		1,326	1,262
Total operating lease expense		<u>\$ 5,735</u>	<u>\$ 5,647</u>
Condensed Consolidated Statements of Cash Flows			
Cash paid for amounts included in the measurement of operating lease liabilities		\$ 4,455	\$ 3,885
ROU assets obtained in exchange for operating lease obligations		278	799
		<i>As of</i>	
Condensed Consolidated Balance Sheets		<i>September 30,</i>	<i>June 30,</i>
		2025	2025
Lease Assets and Liabilities	<i>Balance Sheet Classification</i>		
Operating lease ROU assets	Right-of-use asset	<u>\$ 70,725</u>	<u>\$ 73,399</u>
Operating lease liabilities - current	Operating lease liabilities - current	\$ 13,771	\$ 14,098
Operating lease liabilities - long-term	Operating lease liabilities	80,702	83,960
Total operating lease liabilities		<u>\$ 94,473</u>	<u>\$ 98,058</u>
Weighted average remaining lease term:		7.4 years	7.6 years
Weighted average discount rate:		4.3 %	4.3 %

The following table summarizes payments by date for the Company's operating leases, which is then reconciled to our total lease obligation (in thousands):

	<i>September 30, 2025</i>
Remaining 2026	\$ 12,958
2027	16,710
2028	16,353
2029	15,893
2030	13,436
Thereafter	35,873
Total	<u>\$ 111,223</u>
Less: Amounts representing interest	16,750
Total lease obligations	<u>\$ 94,473</u>

Certain leases include one or more options to renew, with terms that extend the lease term up to five years. Bio-Techne includes the option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, Bio-Techne is not reasonably certain to exercise such options.

Note 7. Supplemental Equity and Accumulated Other Comprehensive Income (Loss):
Accumulated Other Comprehensive Income

The components of Other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges. The accumulated balances related to each component of Other comprehensive income (loss) are summarized as follows (in thousands):

Quarter ended September 30, 2025 (in thousands):

	<i>Unrealized Gains (Losses) on Derivative Instruments</i>	<i>Foreign Currency Translation Adjustments</i>	<i>Total</i>
Balance as of June 30, 2025, net of tax:	\$ 2,536	\$ (62,416)	\$ (59,880)
Other comprehensive income (loss), before tax:			
Amounts before reclassifications	(3,169)	(3,318)	(6,487)
Amounts reclassified out	1,921	613	2,534
Total other comprehensive income (loss), before tax	(1,248)	(2,705)	(3,953)
Tax (expense)/benefit	(417)	(145)	(562)
Total other comprehensive income (loss), net of tax	(1,665)	(2,850)	(4,515)
Balance as of September 30, 2025, net of tax ⁽¹⁾	<u>\$ 871</u>	<u>\$ (65,266)</u>	<u>\$ (64,395)</u>

⁽¹⁾ The Company had a net deferred tax liability for its cash flow hedges of \$0.3 million as of September 30, 2025.

Quarter ended September 30, 2024 (in thousands):

	<i>Unrealized Gains (Losses) on Derivative Instruments</i>	<i>Foreign Currency Translation Adjustments</i>	<i>Total</i>
Balance as of June 30, 2024, net of tax:	\$ 8,102	\$ (86,418)	\$ (78,316)
Other comprehensive income (loss), before tax:			
Amounts before reclassifications	(5,010)	20,659	15,649
Amounts reclassified out	2,599	782	3,381
Total other comprehensive income (loss), before tax	(2,411)	21,441	19,030
Tax (expense)/benefit	(616)	(185)	(801)
Total other comprehensive income (loss), net of tax	(3,027)	21,256	18,229
Balance as of September 30, 2024, net of tax ⁽¹⁾	<u>\$ 5,075</u>	<u>\$ (65,162)</u>	<u>\$ (60,087)</u>

⁽¹⁾ The Company had a net deferred tax liability for its cash flow hedges of \$1.6 million as of September 30, 2024.

Income taxes are not provided for foreign translation relating to permanent investments in international subsidiaries, but tax effects within foreign currency translation adjustments do include impacts from the net investment hedge.

Note 8. Earnings Per Share:

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

	<i>Quarter Ended September 30,</i>	
	<i>2025</i>	<i>2024</i>
Earnings per share – basic:		
Net earnings	\$ 38,185	\$ 33,600
Income allocated to participating securities	(6)	(6)
Income available to common shareholders	\$ 38,179	\$ 33,594
Weighted-average shares outstanding – basic	155,464	158,531
Earnings per share – basic	\$ 0.25	\$ 0.21
Earnings per share – diluted:		
Net earnings	\$ 38,185	\$ 33,600
Income allocated to participating securities	(6)	(6)
Income available to common shareholders	\$ 38,179	\$ 33,594
Weighted-average shares outstanding – basic	155,464	158,531
Dilutive effect of stock options and restricted stock units	898	2,584
Weighted-average common shares outstanding – diluted	156,362	161,115
Earnings per share – diluted	\$ 0.24	\$ 0.21

The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 6.5 million and 4.1 million for the quarters ended September 30, 2025 and 2024, respectively.

Note 9. Share-based Compensation:

During the quarters ended September 30, 2025 and 2024, the Company granted 0.9 million and 0.8 million stock options at weighted average grant prices of \$53.60 and \$74.85 and weighted average fair values of \$18.86 and \$25.32, respectively. During the quarters ended September 30, 2025 and 2024, the Company granted 0.6 million and 0.5 million restricted stock units at a weighted average fair value of \$53.60 and \$74.92, respectively. During the quarters ended September 30, 2025 and 2024, the Company did not grant restricted common stock shares.

Stock options for 1.4 million and 0.6 million shares of common stock with total intrinsic values of \$18.8 million and \$23.5 million were exercised during the quarters ended September 30, 2025 and 2024, respectively.

Stock-based compensation expense, inclusive of payroll taxes, of \$11.7 million and \$10.3 million was included in Selling, general and administrative expenses for the quarters ended September 30, 2025 and 2024, respectively. Additionally, the Company recognized \$0.4 million and \$0.3 million of stock-based compensation costs, inclusive of payroll taxes, in Cost of sales for the quarters ended September 30, 2025 and 2024, respectively. As of September 30, 2025, there was \$64.9 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 2.1 years.

[Table of Contents](#)**Note 10. Other Income / (Expense):**

The components of Other income (expense) in the accompanying Condensed Consolidated Statement of Earnings and Comprehensive Income are as follows (in thousands):

	<i>Quarter Ended September 30,</i>	
	<i>2025</i>	<i>2024</i>
Interest expense	\$ (2,934)	\$ (2,176)
Interest income	971	926
Gain (loss) on equity method investment	294	374
Other non-operating income (expense), net	2,002	1,060
Total other income (expense)	<u>\$ 333</u>	<u>\$ 184</u>

Note 11. Income Taxes:

The Company's effective income tax rate for the first quarter of fiscal 2026 and 2025 was 20.4% and 16.4%, respectively, of consolidated earnings before income taxes, inclusive of discrete items. The change in the Company's tax rate for the quarter ended September 30, 2025 compared to September 30, 2024 was driven by a mix of net income and timing of discrete items.

The Company recognized total net benefits related to discrete tax items of \$3.6 million during the quarter ended September 30, 2025, compared to \$3.0 million of net benefits during the quarter ended September 30, 2024. Share-based compensation excess tax benefit contributed \$0.5 million in the quarter ended September 30, 2025, compared to \$3.3 million in the quarter ended September 30, 2024. The sale of Exosome contributed a tax benefit of \$2.6 million during the quarter ended September 30, 2025. There was no comparable activity during the quarter ended September 30, 2024. The Company recognized total other immaterial net discrete tax benefit of \$0.5 million in the quarter ended September 30, 2025, compared to \$0.3 million of other immaterial net discrete tax expense in the quarter ended September 30, 2024.

Note 12. Segment Information:

The Company's management evaluates segment operating performance based on Operating income before certain charges to Cost of sales and Selling, general and administrative expenses, principally associated with the impact of partially-owned consolidated subsidiaries as well as acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Spatial Biology segments both include consumables, instruments, services, and royalty revenue.

[Table of Contents](#)

The following is financial information relating to the Company's reportable segments (in thousands):

For the Quarter Ended September 30, 2025

	Protein Sciences	Diagnostics and Spatial Biology	Total
Net sales	\$ 202,188	\$ 79,458	\$ 281,646
Other revenue ⁽¹⁾			5,439
Intersegment			(530)
Consolidated net sales			\$ 286,555
Segment operating income			
Cost of sales	50,518	33,737	
Selling, general and administrative	59,766	27,851	
Research and development	14,191	8,992	
Segment operating income	\$ 77,713	\$ 8,878	\$ 86,591
Unallocated amounts			
Amortization of intangibles			(15,350)
Acquisition related expenses and other			(3,351)
Certain litigation charges			(2,408)
Stock based compensation, inclusive of employer taxes			(12,096)
Restructuring and restructuring-related costs			(7,511)
Recovery of assets held-for-sale			6,789
Corporate general, selling, and administrative expenses			(2,433)
Impact of business held-for-sale ⁽¹⁾			(2,573)
Consolidated operating income			\$ 47,658

⁽¹⁾ Includes the quarterly results of a business that has met the held-for-sale criteria as of June 30, 2025.

For the Quarter Ended September 30, 2024

	Protein Sciences	Diagnostics and Spatial Biology	Total
Net sales	\$ 204,535	\$ 83,192	\$ 287,727
Other revenue ⁽¹⁾			2,303
Intersegment			(572)
Consolidated net sales			\$ 289,458
Segment operating income			
Cost of sales	52,498	35,633	
Selling, general and administrative	57,132	33,518	
Research and development	14,364	9,764	
Segment operating income	\$ 80,541	\$ 4,277	\$ 84,818
Unallocated amounts			
Amortization of intangibles			(19,741)
Acquisition related expenses and other			(1,701)
Certain litigation charges			(292)
Stock based compensation, inclusive of employer taxes			(10,637)
Restructuring and restructuring-related costs			(11,022)
Corporate general, selling, and administrative expenses			(1,586)
Impact of business held-for-sale ⁽¹⁾			148
Consolidated operating income			\$ 39,987

⁽¹⁾ Includes the quarterly results of a business that has met the held-for-sale criteria as of December 31, 2023.

[Table of Contents](#)

Note 13. Restructuring:

Fiscal 2025 Restructuring Actions:

During the fourth quarter of fiscal 2025, management engaged in a series of restructuring activities to optimize components of our global manufacturing processes. These activities included adjusting manufacturing locations and protocols of certain products to better align with geographical and customer demand. The Company is expecting to incur costs related to these actions through fiscal 2027, which will be recorded when specified criteria are met.

As part of these actions, certain assets and liabilities associated with the Exosome Diagnostics business were classified as held-for-sale, including \$4.5 million of goodwill allocated on a relative fair value basis at June 30, 2025. As a result of an impairment test performed during fiscal 2025, a cumulative impairment charge of \$83.1 million was recorded. During the quarter ended September 30, 2025, the Company entered into an agreement with a buyer to purchase the Exosome Diagnostics business for approximately \$15.0 million, with approximately \$6.8 million in stock received at closing. Additionally, we recognized a recovery of assets held-for-sale of \$6.8 million during the quarter ended September 30, 2025 recorded within Selling, general, and administrative on the Condensed Consolidated Statements of Earnings. As part of the agreement, the Company and the buyer entered into a promissory note that will mature in September 2029 that requires the buyer to pay four annual installments of \$2.5 million, of which up to \$5.0 million is payable in the stock of the buyer, MDxHealth. As of September 30, 2025, the fair value of the note receivable was approximately \$9.0 million and is included within Other current assets and Other assets on the Condensed Consolidated Balance Sheets.

The restructuring and restructuring-related charges for periods presented were recorded in the Condensed Consolidated Statements of Earnings and Comprehensive Income as follows (in thousands):

	<i>Quarter Ended September 30, 2025</i>	
Cost of sales	\$	1,482
Selling, general and administrative ⁽¹⁾		(1,357)
Total	\$	125

⁽¹⁾ Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general, and administrative costs.

Restructuring and restructuring-related costs by segment are as follows (in thousands):

	<i>Quarter ended September 30, 2025</i>			
	Employee severance	Asset-related and other	Recovery of assets held-for-sale	Total
Protein Sciences	\$ 1,636	\$ 1,572	\$ —	\$ 3,208
Diagnostics and Spatial Biology	2,966	—	(6,789)	(3,823)
Corporate	740	—	—	740
Total	\$ 5,342	\$ 1,572	\$ (6,789)	\$ 125

Table of Contents

The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Accrued expenses in the accompanying Condensed Consolidated Balance Sheets. Other amounts reported as restructuring and restructuring-related costs in the accompanying Condensed Consolidated Statements of Income and Comprehensive Income have been summarized in the notes to the table (in thousands):

	Employee severance ⁽¹⁾	Asset impairment and other ⁽²⁾	Impairment (Recovery) of assets held-for-sale	Total
Expense incurred in the fourth quarter of 2025	\$ 1,041	\$ 11,531	\$ 83,059	\$ 95,631
Cash payments	—	—	—	—
Non-cash adjustments	—	(11,471)	(83,059)	(94,530)
Accrued restructuring actions balance as of June 30, 2025	\$ 1,041	\$ 60	\$ —	\$ 1,101
Expense incurred in the first quarter of 2026	\$ 5,342	\$ 1,572	\$ (6,789)	\$ 125
Cash payments	(3,414)	(1,632)	—	(5,046)
Non-cash adjustments	—	—	6,789	6,789
Accrued restructuring actions balance as of September 30, 2025	\$ 2,969	\$ —	\$ —	\$ 2,969

(1) Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages.

(2) Primarily relates to impairment of inventory and equipment.

In the first quarter of fiscal 2025, the Company announced enterprise-wide restructuring focused on recovering operating margins and optimizing our manufacturing footprint. The Company is expecting to incur costs related to these actions through fiscal 2026, which will be recorded when specified criteria are met. The restructuring and restructuring-related charges for periods presented were recorded in the Condensed Consolidated Statements of Earnings and Comprehensive Income as follows (in thousands):

	Quarter Ended September 30, 2025	Quarter Ended September 30, 2024
Cost of sales	\$ 597	\$ 4,898
Selling, general and administrative ⁽¹⁾	—	5,371
Total	\$ 597	\$ 10,269

(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general, and administrative costs.

Restructuring and restructuring-related costs by segment are as follows (in thousands):

	Three months ended September 30,					
	2025			2024		
	Employee severance	Asset-related and other	Total	Employee severance	Asset-related and other	Total
Protein Sciences	\$ 420	\$ 177	\$ 597	\$ 2,274	\$ 7,417	\$ 9,691
Diagnostics and Spatial Biology	—	—	—	444	—	444
Corporate	—	—	—	134	—	134
Total	\$ 420	\$ 177	\$ 597	\$ 2,852	\$ 7,417	\$ 10,269

[Table of Contents](#)

The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. Other amounts reported as restructuring and restructuring-related costs in the accompanying Condensed Consolidated Statements of Income and Comprehensive Income have been summarized in the notes to the table (in thousands):

	Employee severance ⁽¹⁾	Asset impairment and other ⁽²⁾	Total
Expense incurred in the first quarter of 2025	\$ 2,852	\$ 7,417	\$ 10,269
Incremental expense incurred in remainder of 2025	593	3,555	4,148
Cash payments	(2,223)	(1,131)	(3,354)
Non-cash adjustments	\$ —	\$ (9,841)	\$ (9,841)
Accrued restructuring actions balance as of June 30, 2025	<u>\$ 1,222</u>	<u>\$ —</u>	<u>\$ 1,222</u>
Incremental expense incurred in the first quarter of 2026	420	177	597
Cash payments	(847)	(177)	(1,024)
Accrued restructuring actions balance as of September 30, 2025	<u>\$ 795</u>	<u>\$ —</u>	<u>\$ 795</u>

(1) Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or relocation of certain manufacturing sites.

(2) Primarily relates to impairment of intangibles and inventory as a result of the closure and relocation of certain manufacturing sites.

Note 14. Subsequent Events:

None.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following management discussion and analysis ("MD&A") provides information that we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the effect of acquisitions and changes in foreign currency at the corporate and segment level. We also provide quantitative information about discrete tax items and other significant factors we believe are useful for understanding our results. The MD&A should be read in conjunction with both the unaudited condensed consolidated financial information and related notes included in this Form 10-Q, and MD&A of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended June 30, 2025. This discussion contains various "Non-GAAP Financial Measures" and also contains various "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled "Non-GAAP Financial Measures" and "Forward-Looking Information and Cautionary Statements" located at the end of Item 2 of this report.

OVERVIEW

Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company) develop, manufacture and sell biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

We are committed to providing the life sciences community with innovative, high-quality scientific tools that allow our customers to make extraordinary discoveries and treat and diagnose diseases. We intend to build on Bio-Techne's past accomplishments, high product quality reputation and sound financial position by executing strategies that position us to serve as the standard for biological content in the research market, and to leverage that leadership position to enter the diagnostics and other adjacent markets. The Company's strategic pillars for long-term growth and profitability are grow and leverage the core, capitalize on high potential markets, market expansion through innovation and acquisition, deliver best-in-class customer experience, and develop people through a transformative culture.

Our Protein Sciences segment is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.

RESULTS OF OPERATIONS

Net Sales

Consolidated net sales for the quarter ended September 30, 2025 were \$286.6 million, a decrease of 1% compared to the same prior year period. Organic revenue for the quarter ended September 30, 2025 decreased 1% compared to the prior year, with foreign currency exchange having a favorable impact of 1% and businesses held-for-sale having an unfavorable impact of 1%. Organic revenue for the quarter ended September 30, 2025 was primarily driven by favorable performance by our Diagnostics and Spatial Biology portfolio offset by volume pressure in our Protein Sciences segment.

Gross Margins

Consolidated gross margin for the quarter ended September 30, 2025 was 65.6% compared to 63.2% for the same prior year period. Excluding the impact of costs recognized upon the sale of acquired inventory, amortization of intangibles, stock-based compensation expense, restructuring and restructuring-related costs, and the impact of businesses held-for-sale, adjusted gross margin for the quarter ended September 30, 2025 was 70.2% compared to 69.5% for the quarter ended September 30, 2024. Fluctuations in consolidated gross margin and adjusted gross margin, as a percentage of sales, have primarily resulted from changes in product mix and a reduction in restructuring charges. We expect that, in the future, gross margins will continue to be impacted by the mix of our portfolio growing at different rates as well as future acquisitions.

Table of Contents

A reconciliation of the reported consolidated gross margin percentages, adjusted for acquired inventory sold, intangible amortization, stock compensation expense, restructuring and restructuring-related charges, and the impact of businesses held-for-sale included in Cost of sales, is as follows (in thousands):

	Quarter Ended September 30,	
	2025	2024
Total consolidated net sales	\$ 286,555	\$ 289,458
Business held-for-sale ⁽¹⁾	5,439	2,303
Revenue from recurring operations	\$ 281,116	\$ 287,155
Gross margin - GAAP	\$ 188,112	\$ 183,017
Gross margin percentage - GAAP	65.6 %	63.2 %
Identified adjustments:		
Costs recognized upon sale of acquired inventory	\$ —	\$ 188
Amortization of intangibles	9,439	11,779
Stock-based compensation, inclusive of employer taxes	385	272
Restructuring and restructuring-related costs	2,079	4,898
Impact of business held-for-sale ⁽¹⁾	(2,581)	(558)
Adjusted gross margin	\$ 197,434	\$ 199,596
Adjusted gross margin percentage ⁽²⁾	70.2 %	69.5 %

(1) September 30, 2024 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. September 30, 2025 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025.

(2) Adjusted gross margin percentage excludes both revenue and gross margin for the businesses that met the held-for-sale criteria during the respective periods.

Selling, General and Administrative Expenses

Selling, general and administrative expenses decreased 2% to \$116.2 million for the quarter ended September 30, 2025 from the same prior year period. The decrease in expenses was due to cost management initiatives.

Research and Development Expenses

Research and development expenses increased 2% to \$24.2 million for the quarter ended September 30, 2025 from the same prior year period. The increase in expenses was due to timing of strategic growth investments, offset by cost management initiatives.

Segment Results

Protein Sciences

	Quarter Ended September 30,	
	2025	2024
Net sales (in thousands)	\$ 202,188	\$ 204,535
Operating margin percentage	38.4 %	39.4 %

The Protein Sciences segment's net sales for the quarter ended September 30, 2025 was \$202.2 million, which decreased 1% compared to the same respective prior year period. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's fiscal 2026 and 2025 operating results. Organic revenue for the segment decreased 3%, and foreign currency exchange had a favorable impact of 2%.

The operating margin was 38.4% for the quarter ended September 30, 2025 compared to 39.4% in the comparative prior year period. The segment's operating margin was unfavorably impacted by a reduction in volume leverage.

	Quarter Ended September 30,	
	2025	2024
Net sales (in thousands)	\$ 79,458	\$ 83,192
Operating margin percentage	11.2 %	5.1 %

The Diagnostics and Spatial Biology segment's net sales for the quarter ended September 30, 2025 was \$79.5 million, with a reported decrease of 4% compared to the same respective prior year period. Organic revenue growth was 3% for the first quarter of fiscal 2026, with foreign currency exchange having an immaterial impact. As of June 30, 2025, a business within the Diagnostics and Spatial Biology segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's fiscal 2026 operating results and had an unfavorable impact of 7%.

The operating margin for the segment was 11.2% for the quarter ended September 30, 2025 compared to 5.1% in the comparative prior year period. The segment's operating margin was favorably impacted by the Exosome Diagnostics divestiture and productivity initiatives.

Income Taxes

Income taxes were at an effective rate of 20.4% of consolidated earnings for the quarter ended September 30, 2025, compared to 16.4% for the same respective prior year period. The change in the Company's tax rate for the quarter ended September 30, 2025 was driven by the mix of net income.

The forecasted tax rate as of the first fiscal quarter of 2026 before discrete items is 26.5% compared to the prior year forecasted tax rate before discrete items of 23.6%. Excluding the impact of discrete items, the Company expects the consolidated income tax rate for the remainder of fiscal 2026 to range from 26% to 30%.

[Table of Contents](#)
Net Earnings

Non-GAAP adjusted consolidated net earnings are as follows (in thousands):

	<i>Quarter Ended September 30,</i>	
	<i>2025</i>	<i>2024</i>
Net earnings before taxes - GAAP	\$ 47,991	\$ 40,171
Identified adjustments:		
Amortization of intangibles	15,350	19,741
Amortization of Wilson Wolf intangible assets	2,490	2,490
Acquisition related expenses and other	3,508	1,862
Certain litigation charges	2,408	292
Stock-based compensation, inclusive of employer taxes	12,096	10,637
Restructuring and restructuring-related costs	7,511	11,022
Investment gain and other non-operating income	(2,146)	—
Recovery of assets held-for-sale	(6,789)	—
Impact of business held-for-sale ⁽¹⁾	2,573	(148)
Net earnings before taxes - Adjusted	\$ 84,992	\$ 86,067
Non-GAAP tax rate	22.3 %	21.5 %
Non-GAAP tax expense	\$ 18,953	\$ 18,536
Non-GAAP adjusted net earnings	\$ 66,039	\$ 67,531
Earnings per share - diluted - Adjusted	\$ 0.42	\$ 0.42

⁽¹⁾ September 30, 2024 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. September 30, 2025 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025.

Depending on the nature of discrete tax items, our reported tax rate may not be consistent on a period-to-period basis. The Company independently calculates a non-GAAP adjusted tax rate considering the impact of discrete items and jurisdictional mix of the identified non-GAAP adjustments. The following table summarizes the reported GAAP tax rate and the effective non-GAAP adjusted tax rate for the quarters ended September 30, 2025 and 2024.

	<i>Quarter Ended September 30,</i>	
	<i>2025</i>	<i>2024</i>
GAAP effective tax rate	20.4 %	16.4 %
Discrete items	6.1	7.2
Long-term GAAP tax rate	26.5 %	23.6 %
Rate impact items		
Stock based compensation	(2.7)%	(2.8)%
Other	(1.5)	0.7
Total rate impact items	(4.2)%	(2.1)%
Non-GAAP adjusted tax rate	22.3 %	21.5 %

The difference between the reported GAAP tax rate and non-GAAP tax rate applied to the identified non-GAAP adjustments for the quarter ended September 30, 2025 is primarily a result of discrete tax items, including the tax benefit of stock option exercises.

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents were \$145.0 million as of September 30, 2025, compared to \$162.2 million as of June 30, 2025.

The Company has a line-of-credit governed by a Credit Agreement dated August 31, 2022 that will mature on August 31, 2027. As of September 30, 2025, there is \$700 million available on the line-of-credit. See Note 5 to the Condensed Consolidated Financial Statements for a description of the Credit Agreement.

[Table of Contents](#)

During fiscal year 2022, the Company paid \$25 million to enter into a two-part forward contract which requires the Company to purchase the full equity interest in Wilson Wolf if certain annual revenue or EBITDA thresholds are met. During fiscal year 2023, Wilson Wolf met the EBITDA target and the Company paid an additional \$232 million to acquire 19.9% of Wilson Wolf. Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, which requires the Company to acquire the remaining 80.1% of Wilson Wolf on December 31, 2027. The second part of the contract would be accelerated in advance of December 31, 2027 if Wilson Wolf meets certain financial milestones. As of September 30, 2025, the second milestones have not been met. The second option payment of approximately \$1 billion plus potential contingent consideration is forecasted to occur between fiscal 2026 and fiscal 2028.

Management of the Company expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available cash, cash generated from operations, and remaining credit available on its existing revolving line of credit.

Cash Flows From Operating Activities

The Company generated cash of \$27.6 million from operating activities in the first quarter of fiscal 2026 compared to \$63.9 million in the first quarter of fiscal 2025. The decrease from the prior year was primarily due to changes in the timing of cash payments on certain operating assets and liabilities.

Cash Flows From Investing Activities

We continue to make investments in our business, including capital expenditures.

Capital expenditures for fixed assets for the first quarter of fiscal 2026 and 2025 were \$5.4 million and \$9.2 million, respectively. Capital expenditures for the remainder of fiscal 2026 are expected to be approximately \$27 million. Capital expenditures are expected to be financed through currently available funds and cash generated from operating activities. Expected additions in fiscal 2026 are related to increasing capacity to meet expected sales growth across the Company.

During the first quarter of fiscal 2026, the Company received \$4.6 million for assets held-for-sale. There was no comparable activity in the first quarter of fiscal 2025.

During the first quarter of fiscal 2025, the Company invested \$15.0 million into Spear Bio. There was no comparable activity in the first quarter of fiscal 2026.

During the first quarter of fiscal 2025, certificates of deposit reached maturity for \$1.1 million. There was no comparable activity in the first quarter of fiscal 2026.

The Company received tax distributions of \$1.4 million from its equity method investee during the first quarter of both fiscal 2026 and 2025.

Cash Flows From Financing Activities

During the first quarter of fiscal 2026 and 2025, the Company paid cash dividends of \$12.4 million and \$12.7 million, respectively, to all common shareholders. On November 5, 2025, the Company announced the payment of a \$0.08 per share cash dividend, or approximately \$12.5 million, will be payable November 28, 2025 to all common shareholders of record on November 17, 2025.

Cash of \$23.5 million and \$25.1 million was received during the first quarter of fiscal 2026 and 2025, respectively, from the exercise of stock options.

During the first quarter of fiscal 2026 and 2025, the Company made repayments of \$46.0 million and \$19.0 million, respectively, on its long-term debt balance. The Company did not draw under its revolving line-of-credit facility during the first quarter of fiscal 2026 and 2025.

During the first quarter of fiscal 2026 and 2025, the Company paid taxes of \$9.2 million and \$5.0 million related to taxes on restricted stock, restricted stock units and stock options exercised through a net share settlement.

CRITICAL ACCOUNTING POLICIES

The Company's significant accounting policies are discussed in the Company's Annual Report on Form 10-K for fiscal 2025 and are incorporated herein by reference. The application of certain of these policies requires judgments and estimates that can affect the results of operations and financial position of the Company. Judgments and estimates are used for, but not limited to, valuation of available-for-sale investments, inventory valuation and allowances, valuation of intangible assets and goodwill and valuation of investments in unconsolidated entities. There have been no significant changes in estimates in the quarter ended September 30, 2025 that would require disclosure nor have there been any changes to the Company's policies.

NON-GAAP FINANCIAL MEASURES

This Quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Item 2, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:

- Organic revenue
- Adjusted gross margin
- Adjusted operating margin
- Adjusted net earnings and diluted earnings per share
- Adjusted effective tax rate

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measure of organic revenue represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, the impact of businesses held-for-sale, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculation, as those revenues are not fully attributable to the Company. There was no revenue from partially-owned consolidated subsidiaries in fiscal years 2026 or 2025.

Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, restructuring and restructuring-related costs. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subsection assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries as well as revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.

The Company's non-GAAP adjusted operating margin and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to the transition to a new CEO, goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses).

[Table of Contents](#)

In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition.

The Company's non-GAAP adjusted net earnings, in total and on a per share basis, also excludes gain and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.

The Company periodically reassesses the components of our non-GAAP adjustments for changes in how we evaluate our performance, changes in how we make financial and operational decisions, and considers the use of these measures by our competitors and peers to ensure the adjustments are still relevant and meaningful.

Readers are encouraged to review the reconciliations of the adjusted financial measures used in management's discussion and analysis of the financial condition of the Company to their most directly comparable GAAP financial measures provided within the Company's Condensed Consolidated Financial Statements.

FORWARD LOOKING INFORMATION AND CAUTIONARY STATEMENTS

This quarterly report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those regarding the Company's expectations as to the effect of changes to accounting policies, the amount of capital expenditures for the remainder of the fiscal year, the source of funding for capital expenditure requirements, the sufficiency of currently available funds for meeting the Company's needs, the impact of fluctuations in foreign currency exchange rates, and expectations regarding gross margin fluctuations, increasing research and development expenses, increasing Selling, general and administrative expenses and income tax rates. These statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: integration of newly acquired businesses, the introduction and acceptance of new products, general national and international economic, political, regulatory, and other conditions, increased competition, the reliance on internal manufacturing and related operations, supply chain challenges, the impact of currency exchange rate fluctuations, the recruitment and retention of qualified personnel, the impact of governmental regulation, maintenance of intellectual property rights, credit risk and fluctuation in the market value of the Company's investment portfolio, and unseen delays and expenses related to facility construction and improvements. For additional information concerning such factors, see the Company's Annual Report on Form 10-K for fiscal 2025 as filed with the Securities and Exchange Commission and Part II. Item 1A below.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company's exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure discussed in the Company's Annual Report on Form 10-K for the year ended June 30, 2025.

ITEM 4. CONTROLS AND PROCEDURES***(a) Evaluation of disclosure controls and procedures.***

The Company maintains disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). The Company's management has evaluated, with the participation of its Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of its disclosure controls and procedures as of the end of the period covered in this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2025, our disclosure controls and procedures were effective.

(b) Changes in internal controls over financial reporting.

There were no changes in the Company's internal control over financial reporting during the first quarter of fiscal 2026 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION**ITEM 1. LEGAL PROCEEDINGS**

As of November 5, 2025, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

ITEM 1A. RISK FACTORS

During the quarter ended September 30, 2025, there have been no material changes from the risk factors found in Part I, Item 1A, "Risk Factors," of the Company's Annual Report on Form 10-K for the year ended June 30, 2025.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The Company's repurchase plan approved by the Board on April 30, 2025, granted management the discretion to mitigate the dilutive effect of stock option exercises. The plan authorizes the Company to purchase up to \$505 million in stock. As of September 30, 2025, the Company had \$405.0 million available to repurchase under our existing plan.

Period	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Dollar Amount of Shares that May Yet Be Purchased Under the Plans or Programs
July 1 - July 31, 2025	—	\$ —	—	\$ 405,007,867
August 1 - August 31, 2025	500	48.01	500	404,983,864
September 1 - September 30, 2025	—	—	—	404,983,864
July 1 - September 30, 2025	500	48.01	500	

ITEM 3. DEFAULT ON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

During the quarter ended September 30, 2025, no director or officer of the Company adopted a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in item 408(a) of Regulation S-K.

ITEM 6. EXHIBITS

**EXHIBIT INDEX
TO
FORM 10-Q**

BIO-TECHNE CORPORATION

Exhibit Number	Description
3.1	<u>Amended and Restated Articles of Incorporation of the Company--incorporated by reference to Exhibit 3.1 of the Company's 8-K dated November 1, 2022*</u>
3.2	<u>Fourth Amended and Restated Bylaws of the Company--incorporated by reference to Exhibit 3.1 of the Company's Form 8-K dated April 27, 2022*</u>
31.1	<u>Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>
31.2	<u>Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</u>
32.1	<u>Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>
32.2	<u>Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>
101	The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Earnings and Comprehensive Income, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to the Condensed Consolidated Financial Statements.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BIO-TECHNE CORPORATION
(Company)

Date: November 5, 2025

/s/ Kim Kelderman

Kim Kelderman
President and Chief Executive Officer

Date: November 5, 2025

/s/ James Hippel

James Hippel
Executive Vice President, Chief Financial Officer

CERTIFICATION

I, Kim Kelderman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Bio-Techne Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2025

/s/ Kim Kelderman
Kim Kelderman
President and Chief Executive Officer

CERTIFICATION

I, James Hippel, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Bio-Techne Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonable likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2025

/s/ James Hippel
James Hippel
Executive Vice President, Chief Financial Officer

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Bio-Techne Corporation (the "Company") On Form 10-Q for the quarter ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kim Kelderman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Kim Kelderman

Kim Kelderman
President and Chief Executive Officer
November 5, 2025

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Bio-Techne Corporation (the "Company") On Form 10-Q for the quarter ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James Hippel, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ James Hippel

James Hippel

Executive Vice President, Chief Financial Officer

November 5, 2025
